SalaryGuide
AboutPricingFor Employers

Marketing jobs

7 marketing jobs

Neurocrine Biosciences logo
1 day ago

Assoc. Field Medical Marketing Director (Mid-Atlantic)

Neurocrine Biosciences

Delaware, OH (Remote)Full time$174K/yr – $238K/yr
Neurocrine Biosciences logo
2 weeks ago

Associate Director, Brand Development and Launch - Mood Disorder

Neurocrine Biosciences

San Diego, CA (On-site)Full time$174K/yr – $238K/yr
Neurocrine Biosciences logo
2 weeks ago

Sr. Manager, Brand Development and Launch - Schizophrenia

Neurocrine Biosciences

San Diego, CA (On-site)Full time$158K/yr – $216K/yr
Neurocrine Biosciences logo
2 weeks ago

Scientific Director, Lead Generation Biology

Neurocrine Biosciences

San Diego, CA (On-site)Full time$189K/yr – $257K/yr
Neurocrine Biosciences logo
2 months ago

Sr. HCP Marketing Manager - CAH

Neurocrine Biosciences

San Diego, CA (Unknown)Full time$158K/yr – $216K/yr
Neurocrine Biosciences logo
3 months ago

Assoc. Field Medical Marketing Director

Neurocrine Biosciences

San Diego, CA (On-site)Full time$174K/yr – $238K/yr
Neurocrine Biosciences logo
5 months ago

Brand & Field Medical Marketing Intern – Patient Initiatives

Neurocrine Biosciences

San Diego, CA (On-site)Full time

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

7 jobs
Neurocrine Biosciences logo

Assoc. Field Medical Marketing Director (Mid-Atlantic)

Neurocrine Biosciences

Delaware, OH (Remote)

$174K/yr - $238K/yrIn-houseFull-timeSenior level
1 day ago
Neurocrine Biosciences logo

Associate Director, Brand Development and Launch - Mood Disorder

Neurocrine Biosciences

San Diego, CA (On-site)

$174K/yr - $238K/yrIn-houseFull-timeManager
2 weeks ago
Neurocrine Biosciences logo

Sr. Manager, Brand Development and Launch - Schizophrenia

Neurocrine Biosciences

San Diego, CA (On-site)

$158K/yr - $216K/yrIn-houseFull-timeSenior level8+ years exp.
2 weeks ago
Neurocrine Biosciences logo

Scientific Director, Lead Generation Biology

Neurocrine Biosciences

San Diego, CA (On-site)

$189K/yr - $257K/yrIn-houseFull-timeSenior level12+ years exp.
2 weeks ago
Neurocrine Biosciences logo

Sr. HCP Marketing Manager - CAH

Neurocrine Biosciences

San Diego, CA (Unknown)

$158K/yr - $216K/yrIn-houseFull-timeSenior level8+ years exp.
2 months ago
Neurocrine Biosciences logo

Assoc. Field Medical Marketing Director

Neurocrine Biosciences

San Diego, CA (On-site)

$174K/yr - $238K/yrIn-houseFull-timeMid level
3 months ago
Neurocrine Biosciences logo

Brand & Field Medical Marketing Intern – Patient Initiatives

Neurocrine Biosciences

San Diego, CA (On-site)

In-houseFull-timeIntern/new grad
5 months ago
Neurocrine Biosciences logo
Neurocrine Biosciences

Assoc. Field Medical Marketing Director (Mid-Atlantic)

Delaware, OH (Remote)

$174K/yr – $238K/yrSenior LevelFull time

Posted 1 day ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Owns and leads brand strategy programs, KOL engagement, medical marketing initiatives, and regional insights across HCPs, patients, and advisory boards to optimize campaigns and speaker programs.

Job Description

Responsibilities

  • Brand Strategy
  • Partners actively in brand planning and strategic development across HCP, Patient, and Medical Marketing initiatives as applicable
  • Partners with Marketing leadership to transform field insights and real-world feedback into data-driven program enhancements, optimizing campaign effectiveness and strategic investments to maximize market impact
  • Manages Advisory Board execution end-to-end, including leading participant recruitment to match Needs Assessments, facilitating sessions, and compiling and reporting key insights
  • Ensures that peer-to-peer programs meet the identified educational need within the assigned audience, specialty, and sales regions, by identifying and selecting and/or approving appropriate speakers, ensuring speaker readiness and providing coaching, coordinating events with agency partners, tracking and reporting program insights, and implementing feedback-based improvements
  • Marketing Initiatives, Campaigns, and Investments
  • Manages assigned marketing campaigns and programs, functioning as a core member of the internal Marketing team to oversee projects from concept to execution, including agency partner relationships and deliverables, as well as guiding materials through the promotional review process
  • Acts as Marketing liaison to aligned sales teams, providing education on new and existing brand programs
  • KOL Engagement
  • Responsible for an assigned list of healthcare professionals (HCPs), including coordinating ongoing professional engagements, gathering and documenting insights, and eliciting and reporting feedback

Requirements

  • BS/BA degree in marketing, business, health policy, scientific or related field AND 10+ years of relevant experience in pharmaceutical/biotech marketing and sales strongly preferred OR
  • Master's degree AND 8+ years of similar experience preferred as noted above
  • Therapeutic area experience preferred but not required
  • Strong communicator and skilled diplomat in all venues, including the ability to effectively combine scientific knowledge and communication skills (strong clinical acumen)
  • Strong understanding of legal, compliance, and regulatory environment in pharmaceutical promotions, pharma industry guidelines, and related issues
  • Track record of building strong cross-functional relationships with medical, legal, regulatory, advocacy, compliance, marketing, and corporate communications colleagues
  • Demonstrated capabilities in the areas of strategic thinking, initiative, problem solving, and creativity, with experience effectively applying those skills to product positioning and messaging
  • Able to maintain a consistent focus in an ever-changing environment, ensuring strategic alignment for commercial success
  • Consistently demonstrates enthusiasm, confidence, and the ability to work on multiple tasks simultaneously, as well as prioritizes effectively to meet individual, team, and company goals
  • Demonstrates thought leadership through technical/business expertise, effectively solving complex problems and executing cross-functional initiatives

Preferred

  • Therapeutic area experience preferred but not required
  • Master's degree AND 8+ years of similar experience preferred as noted above

Benefits

  • retirement savings plan (with company match)
  • paid vacation, holiday and personal days
  • paid caregiver/parental and medical leave
  • health benefits to include medical, prescription drug, dental and vision coverage in accordance with the terms and conditions of the applicable plans
Neurocrine Biosciences logo

Neurocrine Biosciences

4.3 Glassdoor

Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. Review our Community Guidelines: https://bit.ly/NeurocrineLinkedInGuidelines*in collaboration with AbbVie

Founded in 1992
San Diego, California, USA
2.1K employees (81 in marketing)
www.neurocrine.com
82% recommend to a friend
100% CEO approval

Traffic Signals

Monthly Visitors
27.8K
Traffic Source Mix
Search
50.8%
Direct
39.5%
Referral
7.1%
Social
1%
Paid
1.5%

Headcount Trend

Current headcount: ~2.1K

Marketing Team

Marketing Team Size
77 (4% of company)
Median Career Experience
16 years
Median Tenure
5 years
Marketing Roles Posted (Last 30 Days)
4

People

Marketing Leadership

Eric Peterman
Eric Peterman
Associate Director, Field Medical Marketing
At the company for 1 year 11 months
Jacqueline Smith
Jacqueline Smith
Associate Brand Director
At the company for 2 years 6 months
Desiree Irvin
Desiree Irvin
Associate Director, HCP Marketing
At the company for 1 year 7 months
Bejan C. Sevvom
Bejan C. Sevvom
Director, INGREZZA LTC HCP Marketing
At the company for 2 years

Funding

Total Funding
$260M
Last Raise
$250M
Post IPO Equity, 11 years ago

Funding History

  • Feb 2015
    Post IPO Equity • $250M
  • Dec 2009
    Post IPO Equity • $10M

Recent News

Neurocrine Biosciences to Host R&D Day on December 16
Dec 9, 2025 • PR Newswire
Neurocrine Biosciences (NBIX): Revisiting Valuation Following Decade-Long VMAT2 Review Publication
Nov 28, 2025 • Yahoo Finance
Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules
Nov 20, 2025 • PR Newswire
A Strong Crenessity Launch And Muscarinic Pipeline Can Propel Neurocrine Biosciences Further
Nov 18, 2025 • Seeking Alpha
Assessing Neurocrine Biosciences (NBIX) Valuation After Recent Share Price Momentum
Nov 12, 2025 • Yahoo Finance
Neurocrine's depression drug is latest asset from Takeda pact to flunk a phase 2 trial
Nov 11, 2025 • Fierce Biotech
A “Surprise” Miss: NBI-1070770 for Major Depressive Disorder Fails in Phase 2 Study
Nov 11, 2025 • Psychiatric Times
Neurocrine’s Depression Drug Delivers ‘Surprise’ Phase II Miss
Nov 11, 2025 • BioSpace
Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder
Nov 10, 2025 • PR Newswire
Neurocrine chalks up a depression drug failure
Nov 10, 2025 • BioPharma Dive
Neurocrine Biosciences Clears Key Benchmark, Hitting 80-Plus RS Rating
Nov 6, 2025 • Investor's Business Daily
How the Narrative Around Neurocrine Biosciences Is Evolving After Recent Results and Analyst Reactions
Nov 5, 2025 • Yahoo Finance
Neurocrine Biosciences stock reaches 52-week high at 154.83 USD
Nov 5, 2025 • Investing.com
Neurocrine pens $880M deal with China's TransThera for red-hot immunology target
Nov 3, 2025 • Fierce Biotech
Neurocrine Biosciences (NBIX): Net Margin Miss Challenges Bullish Earnings Growth Narratives
Oct 30, 2025 • Yahoo Finance
Earnings roundup: Alnylam’s down day, Neurocrine’s head scratch and Biogen’s ‘low quality’ win
Oct 30, 2025 • BioPharma Dive
Neurocrine Biosciences (NBIX): Evaluating Valuation After Q3 Earnings Beat and Pipeline Progress
Oct 29, 2025 • Yahoo Finance
Neurocrine Biosciences Reports Third Quarter 2025 Financial Results
Oct 28, 2025 • PR Newswire
Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates
Oct 28, 2025 • Yahoo Finance
Neurocrine Biosciences Beats Estimates But Wall Street Punishes The Stock
Oct 28, 2025 • 24/7 Wall St.
Examining Neurocrine Biosciences Valuation After 24% Stock Surge and Pipeline Progress in 2025
Oct 25, 2025 • Yahoo Finance
Are You Looking for a Top Momentum Pick? Why Neurocrine Biosciences (NBIX) is a Great Choice
Oct 24, 2025 • Yahoo Finance
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
Oct 21, 2025 • Nasdaq
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
Oct 21, 2025 • Yahoo Finance
Stocks Generating Improved Relative Strength: Neurocrine Biosciences
Oct 20, 2025 • Investor's Business Daily
Lobbying Update: $900,000 of NEUROCRINE BIOSCIENCES INC lobbying was just disclosed
Oct 20, 2025 • Quiver Quantitative
Neurocrine Biosciences: Buy Rated As Q3 2025 Earnings Catalyst Approaches (NASDAQ:NBIX)
Oct 18, 2025 • Seeking Alpha
Neurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA® (valbenazine) 40 mg Capsules
Oct 17, 2025 • PR Newswire
Neurocrine Biosciences (NBIX): Evaluating Valuation Following Recent Clinical Milestones and Leadership Appointment
Oct 11, 2025 • simplywall.st
How New Three-Year INGREZZA Data at Neurocrine Biosciences (NBIX) Has Changed Its Investment Story
Oct 7, 2025 • simplywall.st
A Fresh Look at Neurocrine Biosciences (NBIX) Valuation After Latest INGREZZA Clinical Study Results
Oct 7, 2025 • Yahoo Finance
Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise
Oct 6, 2025 • PR Newswire
Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea
Oct 6, 2025 • PR Newswire
20+ years commercial leader Mike Sibley named Neurocrine SVP & GM, Neuropsychiatry to lead INGREZZA franchise
Oct 6, 2025 • Stock Titan
Neurocrine Biosciences names Mike Sibley to lead neuropsychiatry franchise
Oct 6, 2025 • Investing.com
Neurocrine Biosciences (NBIX): Exploring Valuation After Recent Share Price Movement
Oct 3, 2025 • simplywall.st
Should Neurocrine Biosciences’ (NBIX) Latest Remission Data Shift Investor Expectations for Growth?
Sep 27, 2025 • simplywall.st
Should You be Optimistic on Neurocrine Biosciences (NBIX)?
Sep 25, 2025 • Yahoo Finance
Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA® (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Disease Burden
Sep 23, 2025 • PR Newswire
Neurocrine’s Phase II MDD success raises analyst spirits
Sep 23, 2025 • Clinical Trials Arena
Neurocrine's ingrezza shows efficacy in tardive dyskinesia
Sep 23, 2025 • thefly.com
Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder
Sep 23, 2025 • BioSpace
Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder
Sep 22, 2025 • PR Newswire
Neurocrine announces Phase 2 SAVITRI met primary efficacy endpoint
Sep 22, 2025 • thefly.com
Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder
Sep 22, 2025 • sdbn.org
Neurocrine Biosciences at TD Cowen Summit: Evolving R&D Strategy
Sep 17, 2025 • Investing.com
Transcript : Neurocrine Biosciences, Inc. Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit, Sep-17-2025 12
Sep 17, 2025 • MarketScreener
Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025
Sep 17, 2025 • BioSpace
What Does Wall Street Think About Neurocrine Biosciences (NBIX)?
Sep 16, 2025 • Yahoo Finance
Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025
Sep 16, 2025 • PR Newswire
Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025
Sep 16, 2025 • sdbn.org
Tardive Dyskinesia Treatment Global Market Report 2025| Business Growth, Current and Future Trends till 2029
Sep 15, 2025 • EIN Presswire
New US CIO appointments, September 2025
Sep 10, 2025 • Building industrial AI from the inside out for a stronger digital core | CIO
Neurocrine at Morgan Stanley Conference: Strategic Growth and Innovation
Sep 9, 2025 • Investing.com
Transcript : Neurocrine Biosciences, Inc. Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-09-2025 10
Sep 9, 2025 • MarketScreener
Neurocrine price target raised by $5 at RBC Capital, here's why
Sep 5, 2025 • thefly.com
Neurocrine Biosciences, Inc. (NBIX) Beats Estimates on Neurology Drug Demand, Expands Payer Access
Sep 2, 2025 • Yahoo Finance
IBD Rating Upgrades: Neurocrine Biosciences Flashes Improved Price Strength
Aug 28, 2025 • Investor's Business Daily
Neuroscience Leader Neurocrine Biosciences Sets Extensive Conference Schedule with Key Executives Presenting
Aug 26, 2025 • Stock Titan
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September 2025
Aug 26, 2025 • BioSpace
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
Aug 26, 2025 • PR Newswire
Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
Aug 7, 2025 • BioSpace
Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
Aug 6, 2025 • PR Newswire
Neurocrine Biosciences’ Promising MDD Treatment Study: Key Insights for Investors
Aug 1, 2025 • TipRanks
Neurocrine Biosciences Second Quarter 2025 Earnings: Beats Expectations
Aug 1, 2025 • Yahoo Finance
Neurocrine Biosciences Positioned For Growth And New Potential Blockbusters (NASDAQ:NBIX)
Jul 31, 2025 • Seeking Alpha
Guggenheim raises Neurocrine Bio. stock price target on strong Ingrezza sales
Jul 31, 2025 • Investing.com
Neurocrine Biosciences Reports Second Quarter 2025 Financial Results
Jul 31, 2025 • BioSpace
Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q2 Earnings
Jul 30, 2025 • Yahoo Finance
Earnings call transcript: Neurocrine Biosciences Q2 2025 earnings beat expectations
Jul 30, 2025 • Investing.com
Neurocrine Biosciences Reports Second Quarter 2025 Financial Results
Jul 30, 2025 • PR Newswire
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates
Jul 30, 2025 • Nasdaq
Transcript : Neurocrine Biosciences, Inc., Q2 2025 Earnings Call, Jul 30, 2025
Jul 30, 2025 • MarketScreener
Neurocrine Biosciences Grows Pipeline While Maintaining Steady Investor Confidence
Jul 27, 2025 • Yahoo Finance
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Jul 23, 2025 • Yahoo Finance
Lobbying Update: $890,000 of NEUROCRINE BIOSCIENCES INC lobbying was just disclosed
Jul 21, 2025 • Quiver Quantitative
Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025
Jul 15, 2025 • PR Newswire
Neurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition
Jul 15, 2025 • PR Newswire
Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025
Jul 15, 2025 • BioSpace
Neurocrine Biosciences Reports Positive 1-year Data Of Crenessity In Adults With CAH At ENDO 2025
Jul 14, 2025 • Nasdaq
Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025
Jul 14, 2025 • PR Newswire
Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society’s Annual Meeting
Jul 14, 2025 • BioSpace
Neurocrine Biosciences, Inc. Presents One-Year Data Showing Sustained Efficacy of CRENESSITY in Adult Patients, at ENDO 2025
Jul 14, 2025 • MarketScreener
Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting
Jul 14, 2025 • PR Newswire
Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025
Jul 14, 2025 • sdbn.org
Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025
Jul 14, 2025 • MarketScreener
Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting
Jul 14, 2025 • MarketScreener
Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025
Jul 14, 2025 • Morningstar.com
Untapped Patient Base, Ingrezza Growth Keep Neurocrine (NBIX) on Guggenheim’s Buy List
Jul 10, 2025 • Yahoo Finance
Stocks With Rising Relative Strength: Neurocrine Biosciences
Jul 9, 2025 • Investor's Business Daily
Neurocrine Biosciences: Still A Buy After 30% Uplift Since My Last Coverage (NASDAQ:NBIX)
Jul 4, 2025 • Seeking Alpha
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist
Jun 30, 2025 • PR Newswire
Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea
Jun 27, 2025 • PR Newswire
Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia
Jun 20, 2025 • PR Newswire
Huntington’s Disease Market to Reach $3.2Bn by 2033 Amid Breakthroughs in Gene-Based Therapies | DataM Intelligence
Jun 13, 2025 • EIN Presswire
Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer
Jun 10, 2025 • citybiz
Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer
Jun 10, 2025 • BioSpace
Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer
Jun 9, 2025 • PR Newswire
Neurocrine Biosciences Names Lewis Choi as Chief Information Officer
Jun 9, 2025 • MarketScreener
Huntington’s Disease: Charting a New Path with Disease-Modifying Therapies and Strategic Innovation
Jun 6, 2025 • EIN Presswire